The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
Open accessAbstract
Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF). Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation. Arginine vasopressin (AVP) promotes renal water reabsorption via the V 2 receptor, and its levels are increased in CHF. This study was designed to assess the effects of a single oral dose of tolvaptan, a selective V 2-receptor blocker, in the absence of other medications, on renal function in human CHF and to compare this to the effects of a single oral dose of furosemide. We hypothesized that V 2-receptor antagonism would yield a diuresis comparable to furosemide but would not adversely affect renal hemodynamics, plasma electrolyte concentration, or neurohumoral activation in stable human CHF. Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF. Patients received placebo or 30 mg of tolvaptan on day 1 and were crossed over to the other medication on day 3. On day 5, all subjects received 80 mg of furosemide. Tolvaptan and furosemide induced similar diuretic responses. Unlike tolvaptan, furosemide increased urinary sodium and potassium excretion and decreased renal blood flow. Tolvaptan, furosemide, and placebo did not differ with respect to mean arterial pressure, glomerular filtration rate, or serum sodium and potassium. We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Lee, D. S., Austin, P. C., Rouleau, J. L., Liu, P. P., Naimark, D., & Tu, J. V. (2003) · JAMA · doi:10.1001/jama.290.19.2581 · Cited by 1,272
Nielsen, S., Chou, C. L., Marples, D., Christensen, E. I., Kishore, B. K., & Knepper, M. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1013 · Cited by 1,043
Dries, D. L., Exner, D. V., Domanski, M. J., Greenberg, B., & Stevenson, L. W. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00608-7 · Cited by 879
F�hr, J., Kaczmarczyk, J., & Kr�ttgen, C.-D. (1955) · Klinische Wochenschrift · doi:10.1007/bf01473295 · Cited by 795
Gheorghiade, M. (2004) · JAMA · doi:10.1001/jama.291.16.1963 · Cited by 651
Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome
Obi, Y., Kim, T., Kovesdy, C. P., Amin, A. N., & Kalantar-Zadeh, K. (2016) · Cardiorenal Medicine · doi:10.1159/000441283 · Cited by 614
Increased plasma arginine vasopressin levels in patients with congestive heart failure
Goldsmith, S. R., Francis, G. S., Cowley, A. W., Barry Levine, T., & Cohn, J. N. (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80040-0 · Cited by 484
Cited by
Konstam, M. A. (2007) · JAMA · doi:10.1001/jama.297.12.1319 · Cited by 1,628
Tolvaptan, a Selective Oral Vasopressin V 2 -Receptor Antagonist, for Hyponatremia
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065181 · Cited by 1,215
Self-citationDamman, K., Navis, G., Smilde, T. D. J., Voors, A. A., van der Bij, W., van Veldhuisen, D. J., & Hillege, H. L. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.05.010 · Cited by 471
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Boorsma, E. M., ter Maaten, J. M., Damman, K., Dinh, W., Gustafsson, F., Goldsmith, S., Burkhoff, D., Zannad, F., Udelson, J. E., & Voors, A. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0379-7 · Cited by 365
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Finley, J. J., Konstam, M. A., & Udelson, J. E. (2008) · Circulation · doi:10.1161/circulationaha.108.765289 · Cited by 104
Metadata
- Authors
- Costello-Boerrigter, L. C., Smith, W. B., Boerrigter, G., Ouyang, J., Zimmer, C. A., Orlandi, C., & Burnett, J. C.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2006-02
- Volume
- 290
- Issue
- 2
- Pages
- F273-F278
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W2152859655
- Cited by
- 264
- References
- 27
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. https://app.cochat.ai/papers/10.1152/ajprenal.00195.2005
- The paper
- Costello-Boerrigter, L. C., Smith, W. B., Boerrigter, G., Ouyang, J., Zimmer, C. A., Orlandi, C., & Burnett, J. C. (2006). Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. American Journal of Physiology-Renal Physiology. https://doi.org/10.1152/ajprenal.00195.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.